Bicocca Open Archive

Logo unimib boa
PIAZZA, ROCCO GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.288
AS - Asia 15.800
EU - Europa 13.693
SA - Sud America 2.284
AF - Africa 381
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 27
Totale 57.509
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.474
SG - Singapore 5.511
IT - Italia 3.515
CN - Cina 3.293
DE - Germania 2.652
VN - Vietnam 2.524
HK - Hong Kong 1.864
RU - Federazione Russa 1.762
BR - Brasile 1.711
SE - Svezia 1.237
IE - Irlanda 1.203
GB - Regno Unito 672
FR - Francia 595
UA - Ucraina 593
CA - Canada 591
IN - India 487
FI - Finlandia 358
BD - Bangladesh 282
KR - Corea 281
ID - Indonesia 275
TR - Turchia 252
AR - Argentina 219
IQ - Iraq 178
ES - Italia 171
PL - Polonia 160
JP - Giappone 154
ZA - Sudafrica 148
NL - Olanda 143
AT - Austria 127
MX - Messico 120
CH - Svizzera 110
PK - Pakistan 107
DK - Danimarca 104
SA - Arabia Saudita 104
EC - Ecuador 86
BE - Belgio 79
PH - Filippine 77
VE - Venezuela 74
CO - Colombia 73
UZ - Uzbekistan 68
MA - Marocco 49
LT - Lituania 45
EG - Egitto 39
CL - Cile 36
JO - Giordania 35
KE - Kenya 32
MY - Malesia 32
BG - Bulgaria 31
PE - Perù 30
TN - Tunisia 30
AZ - Azerbaigian 29
CZ - Repubblica Ceca 29
AU - Australia 28
NP - Nepal 26
IR - Iran 25
PY - Paraguay 25
IL - Israele 24
AE - Emirati Arabi Uniti 23
ET - Etiopia 22
EU - Europa 22
TH - Thailandia 22
DO - Repubblica Dominicana 21
CR - Costa Rica 17
OM - Oman 17
BO - Bolivia 16
JM - Giamaica 16
AL - Albania 15
PS - Palestinian Territory 14
KG - Kirghizistan 13
KZ - Kazakistan 13
RO - Romania 13
UY - Uruguay 13
GR - Grecia 12
NO - Norvegia 12
LB - Libano 11
TW - Taiwan 9
DZ - Algeria 8
TT - Trinidad e Tobago 8
HN - Honduras 7
LY - Libia 7
MU - Mauritius 7
RS - Serbia 7
GE - Georgia 6
HU - Ungheria 6
LV - Lettonia 6
NI - Nicaragua 6
PT - Portogallo 6
SN - Senegal 6
AM - Armenia 5
CI - Costa d'Avorio 5
MT - Malta 5
NG - Nigeria 5
NZ - Nuova Zelanda 5
PA - Panama 5
SC - Seychelles 5
SK - Slovacchia (Repubblica Slovacca) 5
SV - El Salvador 5
BM - Bermuda 4
BY - Bielorussia 4
CY - Cipro 4
Totale 57.417
Salva come PNG Salva come JPEG
Città #
Ann Arbor 4.898
Singapore 3.241
Ashburn 2.373
Hong Kong 1.790
Frankfurt am Main 1.634
San Jose 1.575
Milan 1.270
Woodbridge 1.224
Dublin 1.173
Chandler 1.067
Fairfield 965
Houston 785
Dallas 759
Ho Chi Minh City 751
Wilmington 747
New York 655
Hanoi 637
Los Angeles 586
Jacksonville 533
Dearborn 507
Beijing 505
Hefei 465
Santa Clara 452
Seattle 420
Chicago 380
The Dalles 315
Cambridge 307
Princeton 302
Toronto 280
Seoul 264
Shanghai 242
Jakarta 217
Lauterbourg 211
Göttingen 205
São Paulo 203
Buffalo 195
Munich 176
Moscow 172
Nanjing 168
Helsinki 153
Council Bluffs 143
Altamura 142
Orem 121
Lawrence 120
Tokyo 114
Da Nang 109
Warsaw 108
London 107
Boardman 105
Nuremberg 103
Guangzhou 94
Rome 88
Lachine 85
Kent 83
San Diego 82
Chennai 80
Montreal 79
Johannesburg 78
Haiphong 77
Denver 76
Brussels 74
Stockholm 73
Turku 72
Fürstenwalde 71
Atlanta 69
Monza 68
Zurich 65
Vienna 64
Baghdad 63
Romola 63
Fremont 58
Brooklyn 57
Dong Ket 57
Poplar 56
Rio de Janeiro 56
Tashkent 56
Nanchang 55
Andover 54
Tianjin 54
Ottawa 53
Shenyang 52
Boston 51
Lissone 49
Ankara 47
Dhaka 47
Phoenix 47
Kocaeli 46
Riyadh 46
Desio 45
Turin 45
Hải Dương 44
Changsha 42
Biên Hòa 41
Can Tho 41
Hebei 41
Amsterdam 40
Mexico City 39
Assago 38
Thái Nguyên 38
Pune 37
Totale 36.910
Salva come PNG Salva come JPEG
Nome #
Longitudinal cancer evolution from single cells 609
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 602
Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations 552
Personalized therapy design for liquid tumors via optimal control theory 551
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 522
A bioinformatics procedure to identify and annotate somatic mutations in whole-exome sequencing data 511
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 509
An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments 478
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene 458
OncoScore: A novel, Internet-based tool to assess the oncogenic potential of genes 454
ETNK1 mutations promote ROS production and DNA damage through increased mitochondrial activity 454
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 448
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients 446
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 440
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine 434
The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis 426
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 423
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 419
ETNK1 mutations in atypical chronic myeloid leukemia induce a mutator phenotype that can be reverted with phosphoethanolamine 412
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 410
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 407
VERSO: a comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples 407
ETNK1 MUTATIONS INCREASE MITOCHONDRIAL ACTIVITY AND PROMOTE DNA DAMAGE THROUGH ROS PRODUCTION 404
LACE: Inference of cancer evolution models from longitudinal single-cell sequencing data 403
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 397
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 392
Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes 391
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 391
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 391
WHOLE-EXOME SEQUENCING OF A PHILADELPHIA NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENT THROUGH THE EXON-CAPTURE TECHNIQUE 390
A computational procedure to identify and annotate somatic mutations in next-generation sequencing data 385
Variant calling from scRNA-seq data allows the assessment of cellular identity in patient-derived cell lines 385
Hif1a: A putative modifier of hemochromatosis 378
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 377
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 373
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 372
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 371
Idiopathic erythrocytosis: a germline disease? 369
Imatinib long term effects study: three years of follow-up and assessment 366
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 364
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 360
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 359
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 350
VirMutSig: Discovery and assignment of viral mutational signatures from sequencing data 350
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 349
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 347
Control-FREEC viewer: a tool for the visualization and exploration of copy number variation data 346
Integrating mutational profiles and transcriptional data with ASTUTE to elucidate the key molecular functions involved in the pathogenesis of cancer 342
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 342
LACE 2.0: an interactive R tool for the inference and visualization of longitudinal cancer evolution 340
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers 335
Whole-Exome Sequencing Data - Identifying Somatic Mutations 334
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 330
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 329
Human chromosome 18 and acrocentrics: A dangerous liaison 328
Chronic myeloid leukemia: Second-line drugs of choice 325
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 324
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al 322
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 322
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 321
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 321
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 316
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 316
A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation 315
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 314
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 312
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 310
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy 309
Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity 309
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 308
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 308
Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples 307
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 307
Integrated Analysis of Whole-Exome Sequencing and Micrornas Expression in Blast Crisis Transformation of Chronic Myeloid Leukemia 302
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients 301
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation 300
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 297
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 297
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib 294
Read-through transcripts in normal human lung parenchyma are down-regulated in lung adenocarcinoma 294
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 294
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 291
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden 290
Reply to P. Laneuville et al 289
Transcriptomic Profile of Human Osteoblast-like Cells Grown on Trabecular Titanium 287
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias 284
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 282
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 280
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 279
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 278
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 277
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 276
Early detection and improved genomic surveillance of SARS-CoV-2 variants from deep sequencing data 275
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 274
Antibody Deficiency in Patients with Biallelic KARS1 Mutations 271
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 270
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 269
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 268
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 266
EXT 1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses 263
Totale 35.726
Salva come PNG Salva come JPEG
Categoria #
all - tutte 178.021
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 178.021
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021778 0 0 0 0 0 0 0 0 0 0 342 436
2021/20223.341 313 301 354 244 233 295 225 183 183 227 295 488
2022/20235.119 604 1.360 515 520 400 631 90 242 313 100 183 161
2023/20244.287 162 187 223 260 506 1.076 753 151 308 145 97 419
2024/20259.968 486 867 610 551 843 425 673 370 875 1.608 931 1.729
2025/202622.355 2.912 1.643 1.966 2.898 2.700 1.174 3.609 963 1.798 2.159 533 0
Totale 58.764